Researchers from Novo Nordisk and Veradigm have published a new study in the journal Diabetes Therapy, employing de-identified patient data sourced from a nationwide, electronic health record platform and linked to claims data.

IDegLira may be used as an intensification strategy for patients with type 2 diabetes across a range of different baseline therapies, according to a real-world evidence study conducted by researchers at the Medical College of Wisconsin, Novo Nordisk, and Veradigm. Initiation with IDegLira was shown to lower glycated hemoglobin (HbA1c) with minimal impact on weight. Among patients simplifying therapy, reductions in HbA1c were maintained despite reductions in the daily number of injectable antidiabetic medications.

Download this article now at no charge.